Review article
Paradoxical reaction in HIV negative tuberculous meningitis

https://doi.org/10.1016/j.jns.2014.03.025Get rights and content

Highlights

  • A paradoxical reaction is a worsening of tuberculosis lesions or the appearance of a new lesion in patients who improved with treatment.

  • In TBM, a paradoxical reaction does not represent treatment failure.

  • Paradoxical reaction occurs as the result of an exaggerated immune response to mycobacterial antigens.

  • Expansion of existing cerebral tuberculomas or appearance of a new tuberculoma is a frequent manifestation.

  • Paradoxical reaction, like optochiasmatic and spinal arachnoiditis, is devastating.

  • Corticosteroids have a beneficial effect. Mortality is rare.

Abstract

This review focusses on paradoxical reactions occurring during the treatment of tuberculous meningitis (TBM) in human immunodeficiency virus-negative cases. A paradoxical reaction is defined as the worsening of a pre-existing lesion or the appearance of new lesion in a patient whose clinical symptoms initially improved with anti-tuberculosis treatment. A number of different paradoxical reactions have been reported in patients with TBM including expansion of existing cerebral tuberculomas, and appearance of new tuberculomas, hydrocephalus, and optochiasmatic and spinal arachnoiditis. While the exact mechanism of paradoxical reactions is uncertain, an exaggerated immune reaction against Mycobacterium tuberculosis-associated antigens is currently the most accepted theory for tuberculous paradoxical reaction. Corticosteroids are considered to have a beneficial effect in the management of paradoxical reactions. Immuno-modulatory drugs, including tumor necrosis factor-α antagonists, thalidomide and interferon-γ have been used in isolated cases with more severe forms of paradoxical reactions.

Introduction

A paradoxical reaction is defined as the worsening of pre-existing tuberculous lesions or the appearance of new tuberculous lesions in patients whose clinical symptoms initially improved with anti-tuberculosis treatment [1], [2]. Paradoxical reactions must be distinguished from treatment failure, multidrug-resistance, drug toxicity, or clinical deterioration due to another infection or condition. Tuberculous meningitis (TBM) may be a manifestation of tuberculosis (TB)-associated immune reconstitution inflammatory syndrome (IRIS) [3]. IRIS refers to a paradoxical clinical deterioration following the initiation of antiretroviral therapy in patients co-infected with human immunodeficiency virus (HIV) and receiving anti-tuberculosis treatment [4]. High pathogen load and very low CD4+ T cell count are major risk factors of IRIS [4].

In 1974, Thrush and Barwick, for the first time, documented paradoxical reaction in a patient with central nervous system TB, who had multiple tuberculomas and developed a new tuberculoma during treatment with anti-tuberculosis drugs [5]. In 1980, Lees and co-workers described the first report of paradoxical reaction of TBM in 2 female patients, who paradoxically developed multiple cerebral tuberculoma and basal arachnoiditis [6].

Paradoxical reactions in HIV-negative patients have been reported with varying frequencies in literature. In 253 patients with pulmonary and/or extra-pulmonary TB, paradoxical reactions occurred in 1 out of 86 HIV-uninfected patients (< 1%) and IRIS in 21 of 167 HIV-infected patients (13%) [7]. In a cohort of 104 HIV-negative patients with culture-proven TB, paradoxical reactions were observed in 16 patients (15.4%) with a median time to onset of 56 days (range, 20–109 days) [8]. A study of 76 HIV-negative patients with extra-pulmonary TB showed a relatively high incidence of paradoxical reactions, occurring in 19 patients (25%) with median time to onset of 86 days [9]. Carvalho et al. reported paradoxical reactions in 11 of 137 HIV-negative patients having TB (8%) with a median time to onset of 107 days (range, 31–443 days) [10]. In 115 HIV-negative children with pulmonary and extra-pulmonary TB, 12 patients (10%) developed a paradoxical reaction [11]. None of the children in the paradoxical reaction group had received Bacillus Calmette–Guérin (BCG) vaccination, compared to 34 children (33%) in the other group who received BCG vaccination [11]. In a retrospective analysis of 61 HIV-negative patients with TBM, paradoxical changes in cerebrospinal fluid (CSF) were seen in 20 patients (32.8%) [12]. A CSF paradoxical reaction is defined as a progressive increase of lymphocytes or an increase in polymorphonuclear cells instead of lymphocytes.

For this review, we conducted an extensive literature search for case reports of paradoxical reactions occurring in HIV-uninfected patients receiving anti-tuberculosis treatment for TBM. Three cases treated by the authors are also presented.

Section snippets

Paradoxical manifestations

Typical clinical features of TBM include headache, vomiting, meningeal signs, focal neurological deficits, vision loss, cranial nerve palsies, and raised intracranial pressure. The presence of exudates, hydrocephalous, infarction, tuberculoma, and angiographic abnormalities are common neuroimaging abnormalities [13], [14]. During a paradoxical reaction, these clinical and neuroimaging manifestations are either aggravated or appear for the first time during illness, despite adequate

Pathogenesis

TBM is caused by MTB, an aerobic acid-fast pleomorphic bacillus. Transmission occurs primarily by inhalation of airborne droplet nuclei containing MTB into the lungs. MTB multiplies in alveolar macrophages, and soon the bacilli, by hematogenous route, disseminate to brain and other extrapulmonary sites. In the brain, MTB, typically, produces small caseating granulomas in the subpial region of the brain parenchyma. Tuberculous foci (Rich foci) may remain dormant for a long period. TBM develops

Case-1

A 24-year-old lady was admitted with fever, vomiting, and headache for 2 week duration. On examination, neck rigidity was present. CSF analysis showed an elevated protein level of 540 mg/dL, cell count of 90 cells/mm3 (all lymphocytes) and the CSF sugar level was 32 mg/dL. CT of brain was normal. CSF smear examination revealed acid-fast bacilli. She was treated with anti-tuberculous drugs and corticosteroids. There was a marked improvement in the patient with no headache at discharge. Two months

Differential diagnosis

CSF examination is required for the diagnosis of TBM. The “gold standard” for diagnosis is the demonstration of MTB in the CSF. Diagnostic confirmation is done either by Ziehl-Neelsen staining of CSF smear, CSF culture or by detection of the mycobacterial DNA by PCR. However, a majority of patients with TBM are diagnosed on clinical grounds alone without any bacteriological confirmation [13], [14].

It is crucial to recognize the phenomenon of paradoxical reaction, because it usually does not

Treatment

MTB, isolated from CSF of patients with paradoxical reaction is usually sensitive to all first-line anti-tuberculosis drugs [49]. In patients with tuberculous paradoxical reaction, World Health Organization recommended that anti-tuberculosis regimen can be administered without any alteration [61]. When paradoxical reaction, in the form of acute exacerbations, becomes a life-threatening and disabling, treatment with immuno-modulatory drugs may be required. (Table 1)

Prognosis

Reported outcomes are generally favorable in a majority of patients with paradoxical reactions during treatment for TBM. (Table 1) In a series, out of 63 TBM patients, 14 developed tuberculomas following anti-tuberculosis therapy. Eight patients had tuberculoma at inclusion and remaining 41 patients never had tuberculoma. At 12 months, the overall mortality was 14% (3/22) of whom, 2 patients had paradoxical tuberculoma. Although clinical deterioration was seen in patients with paradoxical

Conclusions

In patients with TBM, a paradoxical reaction is often associated with clinical deterioration. However, it does not necessarily represent treatment failure and anti-tuberculosis treatment need not be changed. Corticosteroids are considered to have a beneficial effect in symptomatic patients. Nonetheless, no randomized study is available to demonstrate the precise role of corticosteroids in patients with paradoxical reactions. Some forms of paradoxical reaction, like optochiasmatic and spinal

Conflict of interest

The authors declare that there are no conflicts of interest.

References (130)

  • T. Raut et al.

    Hydrocephalus in tuberculous meningitis: Incidence, its predictive factors and impact on the prognosis

    J Infect

    (2013)
  • B. Singh et al.

    Computed tomography angiography in patients with tuberculous meningitis

    J Infect

    (2012)
  • U.K. Misra et al.

    Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial

    J Neurol Sci

    (2010)
  • D. Dastur et al.

    Spinal meningitides with radiculo-myelopathy. 2. Pathology and pathogenesis

    J Neurol Sci

    (1969)
  • A. Gupta et al.

    Bladder dysfunction and urodynamic study in tuberculous meningitis

    J Neurol Sci

    (2013)
  • P.R. Donald et al.

    Tuberculous meningitis and miliary tuberculosis: the Rich focus revisited

    J Infect

    (2005)
  • B. Sáenz et al.

    The dual face of central nervous system tuberculosis: a new Janus Bifrons?

    Tuberculosis (Edinb)

    (2013)
  • M.K. Matyszak et al.

    Demyelination in the central nervous system following a delayed-type hypersensitivity response to bacillus Calmette–Guérin

    Neuroscience

    (1995)
  • M.K. Matyszak et al.

    Bacillus Calmette–Guérin sequestered in the brain parenchyma escapes immune recognition

    J Neuroimmunol

    (1998)
  • S. Shafiani et al.

    Pathogen-specific Treg cells expand early during mycobacterium tuberculosis infection but are later eliminated in response to Interleukin-12

    Immunity

    (2013)
  • R.K. Gupta et al.

    Central nervous system tuberculosis

    Neuroimaging Clin N Am

    (2011)
  • H.S. Lee et al.

    Adalimumab treatment may replace or enhance the activity of steroids in steroid-refractory tuberculous meningitis

    J Infect Chemother

    (2012)
  • J. Lebas et al.

    Cerebral tuberculomas developing during treatment of tuberculous meningitis

    Lancet

    (1980)
  • M. Reiser et al.

    Paradoxical expansion of intracranial tuberculomas during chemotherapy

    J Infect

    (1997)
  • M.H. Tsai et al.

    Development of tuberculoma during therapy presenting as hemianopsia

    Pediatr Neurol

    (2004)
  • B. Afghani et al.

    Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review

    Clin Infect Dis

    (1994)
  • S. Marais et al.

    Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome

    Clin Infect Dis

    (2013)
  • D.C. Thrush et al.

    Three patients with intracranial tuberculomas with unusual features

    J Neurol Neurosurg Psychiatry

    (1974)
  • N. Lorent et al.

    Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study

    PLoS One

    (2011)
  • V.C. Cheng et al.

    Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients

    Eur J Clin Microbiol Infect Dis

    (2003)
  • G. Geri et al.

    Paradoxical reactions during treatment of tuberculosis with extrapulmonary manifestations in HIV-negative patients

    Infection

    (2013)
  • A.C. Carvalho et al.

    Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients

    Clin Infect Dis

    (2006)
  • C. Olive et al.

    Paradoxical reaction during tuberculosis treatment in immunocompetent children: clinical spectrum and risk factors

    Pediatr Infect Dis J

    (2013)
  • P.N. Sütlas et al.

    Tuberculous meningitis in adults: review of 61 cases

    Infection

    (2003)
  • R.K. Garg

    Tuberculosis of the central nervous system

    Postgrad Med J

    (1999)
  • H.K. Anuradha et al.

    Intracranial tuberculomas in patients with tuberculous meningitis: predictors and prognostic significance

    Int J Tuberc Lung Dis

    (2011)
  • A. Unal et al.

    Clinical and radiological features of symptomatic central nervous system tuberculomas

    Eur J Neurol

    (2005)
  • A. Anupriya et al.

    Tuberculous optochiasmatic arachnoiditis

    Neurol India

    (2010)
  • H.K. Anuradha et al.

    Predictors of stroke in patients with tuberculous meningitis and its effect on the outcome

    Q J Med

    (2010)
  • R.K. Gupta et al.

    MRI in intraspinal tuberculosis

    Neuroradiology

    (1994)
  • T. Srivastava et al.

    Asymptomatic spinal arachnoiditis in patients with tuberculous meningitis

    Neuroradiology

    (2003)
  • A. Moghtaderi et al.

    Paradoxical progression of conus tuberculoma during chemotherapy of tuberculous meningitis

    Neurol India

    (2007)
  • J.S. Citow et al.

    Intramedullary tuberculoma of the spinal cord: case report

    Neurosurgery

    (1994)
  • P. Skendros et al.

    Intradural, extramedullary tuberculoma of the spinal cord as a complication of tuberculous meningitis

    Infection

    (2003)
  • N. Muthukumar et al.

    En plaque intradural extramedullary spinal tuberculoma and concurrent intracranial tuberculomas: paradoxical response to antituberculous therapy. Case report

    J Neurosurg Spine

    (2007)
  • A. Moghtaderi et al.

    Syringomyelia: an early complication of tuberculous meningitis

    Trop Doct

    (2006)
  • A.K. Daif et al.

    Syringomyelia developing as an acute complication of tuberculous meningitis

    Can J Neurol Sci

    (1997)
  • S. Pandey et al.

    Early syringomyelia in tubercular meningitis: a rare occurrence

    J Neurol Res

    (2013)
  • J.C. Garcia-Monco et al.

    The therapeutic paradox in the diagnosis of tuberculous meningitis

    Neurology

    (2005)
  • R. Teoh et al.

    Polymorphonuclear pleocytosis in the cerebrospinal fluid during chemotherapy for tuberculous meningitis

    J Neurol

    (1986)
  • Cited by (74)

    • Paradoxical tuberculosis reaction

      2024, Revue de Medecine Interne
    View all citing articles on Scopus
    View full text